Acute toxicity and outcome among pediatric allogeneic hematopoietic transplant patients conditioned with treosulfan-based regimens

References

• Satwani P, Cooper N, Rao K, Veys P, Amrolia P. Reduced intensity conditioning and allogeneic stem cell transplantation in childhood malignant and non-malignant diseases. Bone Marrow Transplant. 2008;41(2):173–182. doi:10.1038/sj.bmt.1705923.
   PubMed Web of Science ®Google Scholar
• Mohty M, Malard F, Savani BN. High-dose total body irradiation and myeloablative conditioning before allogeneic hematopoietic cell transplantation: time to rethink? Biol Blood Marrow Transplant. 2015;21(4):620–624. doi:10.1016/j.bbmt.2014.09.010.
   PubMed Web of Science ®Google Scholar
• Bresters D, Emons JA, Nuri N, et al. Ovarian insufficiency and pubertal development after hematopoietic stem cell transplantation in childhood. Pediatr Blood Cancer. 2014;61(11):2048–2053. doi:10.1002/pbc.25162.
   PubMed Web of Science ®Google Scholar
• Panasiuk A, Nussey S, Veys P, et al. Gonadal function and fertility after stem cell transplantation in childhood: comparison of a reduced intensity conditioning regimen containing melphalan with a myeloablative regimen containing busulfan. Br J Haematol. 2015;170(5):719–726. doi:10.1111/bjh.13497.
   PubMed Web of Science ®Google Scholar
• Ferrara JLM, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373(9674):1550–1561. doi:10.1016/S0140-6736(09)60237-3.
   PubMed Web of Science ®Google Scholar
• Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy a an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood. 1998;91(3):756–763. doi:10.1182/blood.V91.3.756.
   PubMed Web of Science ®Google Scholar
• Casper J, Knauf W, Blau I, et al. Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation. Ann Hematol. 2004;83(Suppl 1):S70–S71.
   PubMedGoogle Scholar
• Satwani P, Harrison L, Morris E, Del Toro G, Cairo MS. Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and non-malignant diseases: end of the beginning and future challenges. Biol Blood Marrow Transplant. 2005;11(6):403–422. doi:10.1016/j.bbmt.2005.04.002.
   PubMed Web of Science ®Google Scholar
• Styczynski J, Tallamy B, Waxman I, et al. A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematolopoietic SCT in children and adolescents. Bone Marrow Transplant. 2011;46(6):790–799. doi:10.1038/bmt.2010.209.
   PubMed Web of Science ®Google Scholar
• Danylesko I, Shimoni A, Nagler A. Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike. Bone Marrow Transplant. 2012;47(1):5–14. doi:10.1038/bmt.2011.88.
   PubMed Web of Science ®Google Scholar
• Główka F, Kasprzyk A, Romański M, et al. Pharmacokinetics of treosulfan and its active monoepoxide in pediatric patients after intraveneous infusion of high-dose treosulfan prior to HSCT. Eur J Pharm Sci. 2015;68:87–93. doi:10.1016/j.ejps.2014.12.010.
   PubMed Web of Science ®Google Scholar
• ten Brink MH, Zwaveling J, Swen JJ, Bredius RG, Lankester AC, Guchelaar HJ. Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics. Drug Discov Today. 2014;19(10):1572–1586. doi:10.1016/j.drudis.2014.04.005.
   PubMed Web of Science ®Google Scholar
• Stoep MYEC, Zwaveling J, Bertaina A, et al. Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation. Br J Clin Pharmacol. 2019;85(9):2033–2044. doi:10.1111/bcp.13995.
   PubMed Web of Science ®Google Scholar
• van der Stoep M, Bertaina A, Ten Brink MH, et al. High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study. Br J Haematol. 2017;179(5):772–780. doi:10.1111/bjh.14960.
   PubMed Web of Science ®Google Scholar
• Greystoke B, Bonanomi S, Carr TF, et al. Treosulfan-containing regimes achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities. Br J Haematol. 2008;142(2):257–262. doi:10.1111/j.1365-2141.2008.07064.x.
   PubMed Web of Science ®Google Scholar
• Geyer MB, Jacobson JS, Freedman J, et al. A comparison of immune reconstitution and graft-versus host-disease following myeloablative conditioning versus reduced toxicity conditioning and umbical cord blood transplantation in pediatric recipients. Br J Haematol. 2011;155(2):218–234. doi:10.1111/j.1365-2141.2011.08822.x.
   PubMed Web of Science ®Google Scholar
• Beier R, Schulz A, Hönig M, et al. Long-term follow-up of children conditioned with treosulfan: German and Austrian experience. Bone Marrow Transplant. 2013;48(4):491–501. doi:10.1038/bmt.2012.188.
   PubMed Web of Science ®Google Scholar
• Dinur-Schejter Y, Krauss AC, Erlich O, et al. Bone marrow transplantation for non-malignant diseases using treosulfan-based conditioning. Pediatr Blood Cancer. 2015;62(2):299–304. doi:10.1002/pbc.25267.
   PubMed Web of Science ®Google Scholar
• Strullu M, Rialland F, Cahu X, et al. Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning regimen: a single-center experience. Eur J Haematol. 2012;88(6):504–509. doi:10.1111/j.1600-0609.2012.01776.x.
   PubMed Web of Science ®Google Scholar
• Ruutu T, Volin L, Beelen DW, et al. Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. Haematologica. 2011;96(9):1344–1250. doi:10.3324/haematol.2011.043810.
   PubMed Web of Science ®Google Scholar
• Wachowiak J, Sykora KW, Cornish J, et al. EBMT Peditric Diseases Working Party. Treosulfan-based preparative regimens for allo-HSCT in childhood haematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party. Bone Marrow Transplant. 2011;46(12):1510–1518. doi:10.1038/bmt.2010.343.
   PubMed Web of Science ®Google Scholar
• Casper J, Holowiecki J, Trenschel R, et al. Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning. Bone Marrow Transplant. 2012;47(9):1171–1177. doi:10.1038/bmt.2011.242.
   PubMed Web of Science ®Google Scholar
• Beelen DW, Trenschel R, Stelljes M, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol. 2020;7:e28–e39. doi:10.1016/S2352-3026(19)30157-7.
   PubMed Web of Science ®Google Scholar
• Boztug H, Zecca M, Sykora KW, et al. Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukemia. Ann Hematol. 2015;94(2):297–306. doi:10.1007/s00277-014-2196-8.
   PubMed Web of Science ®Google Scholar
• Boztug H, Sykora KW, Slatter M, et al. European Society for Blood and Marrow Transplantation analysis of treosulfan conditioning before hematopoietic stem cell transplantation in children and adolescents with haematological malignancies. Pediatr Blood Cancer. 2016;63(1):139–148. doi:10.1002/pbc.25764.
   PubMed Web of Science ®Google Scholar
• Schmitt M, Trenschel R, Sayer HG, et al. Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non-Hodgkin lymphoma. Mol Clin Oncol. 2014;2(5):773–782. doi:10.3892/mco.2014.300.
   PubMedGoogle Scholar
• Beier R, Albert MH, Bader P, et al. Allo-SCT using BU, CY and melphalan for children with AML in second CR. Bone Marrow Transplant. 2013;48(5):651–656. doi:10.1038/bmt.2012.204.
   PubMed Web of Science ®Google Scholar
• Beelen DW, Trenschel R, Casper J, et al. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant. 2005;35(3):233–241. doi:10.1038/sj.bmt.1704784.
   PubMed Web of Science ®Google Scholar
• Munkelt D, Koehl U, Kloess S, et al. Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients. Cancer Chemother Pharmacol. 2008;62(5):821–830. doi:10.1007/s00280-007-0669-3.
   PubMed Web of Science ®Google Scholar
• Slatter MA, Rao K, Amrolia P, et al. Treosulfan-based conditioning regimen in children with primary immunodeficiency: United Kingdom experience. Blood. 2011;117(16):4367–4375. doi:10.1182/blood-2010-10-312082.
   PubMed Web of Science ®Google Scholar
• Bernardo ME, Piras E, Vacca A, et al. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood. 2012;120(2):473–476. doi:10.1182/blood-2012-04-423822.
   PubMed Web of Science ®Google Scholar
• Burroughs LM, Shimamura A, Talano JA, et al. Allogeneic hematopoietic cell transplantation using treosulfan-based conditioning for treatment of marrow failure disorders. Biol Blood Marrow Transplant. 2017;23(10):1669–1677. doi:10.1016/j.bbmt.2017.06.002.
   PubMed Web of Science ®Google Scholar
• Morillo-Gutierrez B, Beier R, Rao K, et al. Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience. Blood. 2016;128(3):440–448. doi:10.1182/blood-2016-03-704015.
   PubMed Web of Science ®Google Scholar
• Slatter MA, Boztug H, Pötschger U, et al. EBMT inborn errors and paediatric diseases working parties. Treosulfan-based conditioning for allogeneic haematopoietic stem cell transplantation in children with non-malignant disease. Bone Marrow Transplant. 2015;50(12):1536–1541. doi:10.1038/bmt.2015.171.
   PubMed Web of Science ®Google Scholar